



Biolipox Year-End Report 2006

- Revenues for the year amounted to SEK 40.5 million (147.0). For the fourth quarter revenues amounted to SEK 7.8 million (147.0).
- Earnings after tax for the year amounted to SEK -70.5 million (34.7). For the fourth quarter earnings after tax amounted to SEK -21.3 million (112.6).
- Earnings per share for the year was SEK -98.50 (7.80). For the fourth quarter earnings per share was SEK -28.37 (105.56).
- Cash flow for the year was negative and amounted to SEK -32.4 million (156.6). For the fourth quarter cash flow was negative and amounted to SEK -23.6 million (88.1).
- Biolipox selects a new class of drug candidate in asthma project.
- Biolipox determines formulation of new allergy drug.
- Biolipox strengthens the R&D organization.

Forthcoming financial information

- | | |
|--|-----------------|
| • Interim report, January – March 2007 | 10 May 2007 |
| • Interim report, January – June 2007 | 29 August 2007 |
| • Interim report, January – September 2007 | 18 October 2007 |

Biolipox's year-end report 2006 is presented on the following pages.

For further information, please contact:

Torbjörn Bjerke, President & CEO, Tel: +46-70-866 19 90,

e-mail: torbjorn.bjerke@biolipox.com

Peter Hein, VP & CFO, Tel: +46-8-524 831 10, or +46-73-370 73 43,

e-mail: peter.hein@biolipox.com

About Biolipox

Biolipox is a Swedish research-intense pharmaceutical company. The core of Biolipox's operations is world-leading research on arachidonic acid and its effects on inflammatory diseases - particularly asthma, chronic obstructive pulmonary disease (COPD), rhinitis, pain and arthritis. Through the in-house knowledge in the inflammatory research area, particularly arachidonic acid metabolism, Biolipox has created a portfolio of potential blockbusters in these therapeutic areas. The company has 47 employees and is owned by HealthCap, Apax Partners, Sofinnova Partners, SLS Venture, Crédit Agricole Private Equity, Auriga Partners and the scientific founders.

Biolipox Year-End Report 2006

- Revenues for the year amounted to SEK 40.5 million (147.0). For the fourth quarter revenues amounted to SEK 7.8 million (147.0).
- Earnings after tax for the year amounted to SEK -70.5 million (34.7). For the fourth quarter earnings after tax amounted to SEK -21.3 million (112.6).
- Earnings per share for the year was SEK -98.50 (7.80). For the fourth quarter earnings per share was SEK -28.37 (105.56).
- Cash flow for the year was negative and amounted to SEK -32.4 million (156.6). For the fourth quarter cash flow was negative and amounted to SEK -23.6 million (88.1).
- Biolipox selects a new class of drug candidate in asthma project.
- Biolipox determines formulation of new allergy drug.
- Biolipox strengthens the R&D organization.

Biolipox selects a drug candidate in asthma project

Eoxin enzyme inhibitors – a new class of drugs for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD)

During the fourth quarter, Biolipox has selected a drug candidate for the development of a new asthma drug. Thus, the company moves closer to the clinical phase for a completely new class of drugs, known as the eoxin inhibitors, for the treatment of inflammatory respiratory diseases, such as asthma and COPD. For these major diseases there is a significant need for safe and effective treatment. The eoxins, which are formed from arachidonic acid and have been shown to be involved in inflammatory processes, were discovered by Biolipox's scientific founders and led to the establishment of the company in the year 2000.

Asthma is a chronic inflammatory disease that affects 6 to 8 percent of the adult population and about 10 percent of the children in the Western world. It causes chest symptoms such as shortness of breath, coughing and wheezing. As a result of a contraction of the respiratory muscles and increased mucus production, an acute episode of shortness of breath is experienced. In the more severe cases, such episodes are medical emergencies.

COPD is a permanent pulmonary inflammation (chronic bronchitis), combined with shortness of breath and impaired lung function. The inflammation brings about increased mucus production, lesions in the airway wall and lung tissue, which combined cause obstruction, thereby restricting air flow and respiration. COPD is usually caused by smoking and is a serious and incurable disease for which effective treatment is lacking. COPD affects 6 to 8 percent of the adult population.

The market for asthma and COPD drugs amounted to about USD 16.9 billion in 2005 (Source: SG Cowen & Co, Therapeutic Category Outlook, March 2006).

Biolipox determines formulation of new allergy drug

NLA Nasal Spray – Rapid onset of effect for treatment of allergic and non-allergic rhinitis

In phase II studies, a nasal spray for treatment of allergic and non-allergic rhinitis has shown rapid onset of effect and good efficacy. With a rapid onset of effect, therapy can be initiated on-demand. Local nasal therapy also reduces the risk of systemic side effects such as sedation.

During the year, the NLA formulation has been optimized, and a final formulation selected. This formulation will be tested in a clinical phase II study during 2007.

Rhinitis gives rise to an inflamed swelling in the mucous membranes of the nose, which can result in nasal congestion, itch, and sneezing. Rhinitis can be allergic or non-allergic, and the prevalence has increased sharply during the past 20 years. It is estimated that approximately 25 percent of the Western world population is afflicted.

Sales of drugs for treatment of rhinitis amounted to about USD 6.7 billion in 2005 (Source: SG Cowen & Co, Therapeutic Category Outlook, March 2006).

Selective PGE₂ inhibitor – an effective anti-inflammatory treatment with few side effects

The project, that is being developed in collaboration with Boehringer Ingelheim GmbH, Germany, aims at developing a new, effective medicine for inhibiting pain, inflammation and fever, with less side effects than existing drugs. It is based on the discovery of a specific enzyme, PGE₂ synthase (mPGES), which is involved in the production of prostaglandin E₂, an endogenous substance that is central to various inflammatory processes.

The non-steroidal anti-inflammatory drugs currently available are so-called cyclooxygenase inhibitors (COX-inhibitors), either non-selective COX-inhibitors such as Aspirin®, or selective COX-2 inhibitors such as Celebrex®. They act by blocking all or part of the first step in the formation of prostaglandins. This broad-based effect gives rise to side effects, since many prostaglandins are inhibited, including those necessary for the body's proper functioning. Selective inhibition of the formation of prostaglandin E₂, which is the main inducer of pain and inflammation, markedly reduces the risk of side effects.

One out of three adults and nearly 300 000 children in the U.S. suffer from arthritis. The most common type of arthritis is osteoarthritis, which gives rise to pain and impaired mobility. It is seen in many people as they age, although it may affect younger patients as a result of injury or overuse. Rheumatoid arthritis, inflammation in several joints simultaneously, is somewhat less common, but often more disabling. It also affects young people in their active years, leading to great suffering and a high cost to society at large.

Sales of non steroidal anti-inflammatory drugs in 2005 amounted to about USD 15.0 billion (Source: SG Cowen & Co, Therapeutic Category Outlook, March 2006).

Dual effect respiratory drug – a new class of drugs for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD)

Biolipox is working on a dual effect respiratory drug with potentially both bronchodilatory and anti-inflammatory properties. Several molecules that work well in cell systems have been

identified. Patents to protect substances of interest are filed continuously. The next step is to identify a molecule which corresponds to predefined criteria to be taken into clinical development.

Biolipox strengthens the R&D organization

Biolipox strengthened its R&D organization during the period with eight new employees, whereof three with a PhD. The company now has 47 employees, of whom 42 people work in the R&D organization.

During the third quarter, Dr Göran Tornling was appointed as new Chief Medical Officer and became member of the Executive Management of Biolipox. Prior to joining Biolipox, Dr Tornling held a position as Medical Science Director at AstraZeneca R&D Lund, Sweden. Göran Tornling holds a board certificate in Respiratory and Occupational Medicine and is an Associate Professor of Pulmonary Medicine at Karolinska Institutet. He has published more than 70 original scientific articles and will maintain part-time research activities at Karolinska Institutet.

Revenues and costs 1 January – 31 December 2006

Revenues

Revenues for the year amounted to SEK 40.5 million, of which SEK 7.8 million the fourth quarter. The income during 2006 comprises research funding according to a research and license agreement with Boehringer Ingelheim which was entered into in 2005 and which relates to a selective PGE₂ inhibitor project. In 2005 revenues amounted to SEK 147.0 million of which all was reported during the fourth quarter. This income comprised upfront payment, i.e. compensation received upon contract signing, and research funding, both related to the collaboration with Boehringer Ingelheim.

Costs

Research and development costs increased during the year by 11 percent to SEK 91.7 million (82.7). For the fourth quarter they increased to SEK 26.4 million (23.2), corresponding to a 14 percent increase. Increased costs are mainly due to strengthening of the internal research and development organisation. Of the total R&D costs during the year, SEK 26.0 million (27.7) were related to contract research and costs for external pharmaceutical and pre-clinical development.

Administrative expenses decreased by 5 percent to SEK 27.2 million (28.6). The decrease is due to reduced costs for personnel, which is explained by lower bonus costs in 2006, and the fact that administrative staff has been reduced in Biolipox since last year. During the fourth quarter, administrative expenses decreased by 37 percent to SEK 6.1 million (9.7). This decrease is due to reduced costs for personnel and business development. Administrative expenses include costs for functions such as accounts and finance, legal, HR, business development, external communications, the President & CEO and fees for Board members.

Other operating income amounted to SEK 2.0 million (1.8), mainly comprising invoiced compensation for counselling provided to other companies, exchange gains arising on accounts receivable, accounts payable and bank balances in foreign currency, and grants from the EU regarding the EICOSANOX project. The increase in other operating income is

primarily due to increased income from consulting assignments. Other operating costs amounted to SEK 1.0 million (2.0), consisting of exchange losses arising on accounts receivable, accounts payable and bank balances in foreign currency. The net of exchange gains and exchange losses relating to operations amounted to SEK -0.3 million (-1.3).

The Group's net financial income amounted to SEK 7.0 million (-0.7). The improvement is due to exchange gains on forward exchange agreements and increased financial income, principally stemming from higher interest-bearing bank balances and short-term investments.

Earnings

Earnings after tax amounted to SEK -70.5 million (34.7). During the fourth quarter earnings after tax amounted to SEK -21.3 million (112.6).

Investments and cash-flow

The cash flow for 2006 was negative and amounted to SEK -32.4 million (156.6). The cash-flow for the fourth quarter was negative at an amount of SEK -23.6 million (88.1).

Cash-flow from operating activities was negative at an amount of SEK -27.8 million (24.2) for the year and negative at an amount of SEK -22.0 million (89.5) for the fourth quarter. During the year a substantial decrease in working capital, SEK 33.9 million, had a positive effect and the company's loss had a negative effect on cash flow. The decrease in working capital is mainly due to a withheld preliminary tax being refunded from foreign tax authorities.

Investing activities pertaining to capital investments in machinery and equipment, mainly research instruments for the company's laboratories and to some extent computers and office equipment, used cash of SEK 8.2 million (2.0) during the year. The increase is related to investments at Biolipox's laboratories at Karolinska Institutet, with the purpose to reduce the need for external laboratories.

Financing activities provided cash of SEK 3.6 million during the year, from new financial leasing agreements. During previous year, financing activities provided cash of SEK 134.4 million due to proceeds from a new share issue.

The group's liquid funds on 31 December 2006, including bank balances and short term investments, amounted to SEK 154.8 million (187.2). In addition, current shareholders have agreed to provide another MEUR 15 (about MSEK 135) before 31 December 2008. For this purpose 2,670,890 warrants were issued in conjunction with the new share issue of preferential shares of series P6 in January 2005.

Warrants and incentive program

At the annual general meeting on 10 May 2006 it was decided to issue 400,000 warrants to the subsidiary Pyrinox AB to enable issuance of stock options to primarily employees and for the purpose of financial hedge for these stock options. Each warrant gives the holder the right to acquire one common stock of Biolipox. The company's share capital could increase by SEK 40,000 if all warrants are used. Biolipox has issued a total of 1,280,500 warrants to the subsidiary Pyrinox AB to cover future redemption of stock options and the social security costs associated with issued stock options.

During the fourth quarter 2006 a total of 202,000 stock options have been issued to management and other employees. The stock options give the right to acquire the same number of newly issued common shares at the nominal value SEK 0.10 per share until 31 December 2016. As per 31 December 2006, Biolipox has a total of 876,731 stock options outstanding.

Personnel

At 31 December 2006 Biolipox had 47 (39) employees, while the average number of employees during the year amounted to 43 (39). At the end of the year 42 employees were engaged in the company's research and development and 5 employees were engaged in accounts and finance, business development and management.

Business segments

The operations of Biolipox consist of research and development within certain development stages of pharmaceutical projects. These development projects are in several respects of similar nature and any future products would address similar therapeutic areas and utilize similar distribution channels. Since the company currently has no product sales, the company's operations are currently not divided into lines of business or geographic segments. Under these conditions the company's operations are presented in one segment.

Contingent assets and liabilities

Biolipox has no contingent assets or liabilities, which is no change from the financial year opening.

Post-statement events

The company has no significant post-statement events to report.

Accounting principles

As from the fiscal year 2006 Biolipox applies International Financial Reporting Standards (IFRS). This report has been prepared in accordance with IAS 34 Interim Reports. The transition to IFRS accounting has resulted in the following changes:

- Share-based incentive programs are being expensed (IFRS 2)
Present stock option plans give the right to purchase shares and their fair value at grant date is determined using Black & Scholes model. They are accounted for as personnel costs beginning at the start of the vesting period and is distributed over the vesting period. The corresponding amount is simultaneously accounted for as an increase of equity. Provisions for social costs related to the stock option plans are based on the fair value of the options at the end of the reporting period.
- Forward exchange agreements are accounted for at fair value (IAS 39)
According to IAS 39, the company's forward exchange agreements do not qualify for hedge accounting, meaning that from 1 January 2006, unrealized gains and losses from hedging are recognized as financial items on the income sheet.

Comparative figures relating to previous accounting periods have been restated according to the new accounting principles.

All other accounting principles, valuation principles and calculation methods remain unchanged compared with those applied when compiling the annual report for the 2005 fiscal year.

Annual General Meeting and dividend

The Annual General Meeting of shareholders in Biolipox will be held on 10 May 2007 in Stockholm. The board of directors will propose to the Annual General Meeting that no dividend is paid for the financial year 2006. In regard to the company's early stage of development, the company is not expected to pay a dividend for the next few years.

Annual report

The Annual Report will be available at Biolipox' website from the end of March. The report will also be sent to the shareholders by mail in mid April.

Consolidated income statement

Amount in SEK millions	Jan-Dec 2006	Jan-Dec 2005	Oct-Dec 2006	Oct-Dec 2005
Net revenue	40.5	147.0	7.8	147.0
Gross profit/loss	40.5	147.0	7.8	147.0
Other operating revenues	2.0	1.8	0.5	0.9
Administrative costs	-27.2	-28.6	-6.1	-9.7
Research and development costs	-91.7	-82.7	-26.4	-23.2
Other operating costs	-1.0	-2.0	-0.3	-1.8
Operating profit/loss	-77.5	35.4	-24.5	113.1
Interest income and similar items	7.2	2.1	1.6	0.3
Interest expense and similar items	-0.2	-2.8	1.7	-0.9
Profit/loss after financial items	-70.5	34.7	-21.3	112.6
Tax on earnings for the period	-	-	-	-
Net profit/loss for the period	-70.5	34.7	-21.3	112.6
Earnings per share, SEK ^{1,3}	-98.50	7.80	-28.37	105.56
Earnings per share after full dilution, SEK ^{2,3}	-98.50	3.65	-28.37	11.86
Number of shares at end of period	1,000,000	1,000,000	1,000,000	1,000,000
Average number of shares outstanding	1,000,000	1,000,000	1,000,000	1,000,000
Number of ordinary shares and potential ordinary shares at end of period	13,164,135	12,764,135	13,164,135	12,764,135
Average number of ordinary shares and potential ordinary shares	10,074,075	9,493,186	10,074,075	9,493,186

¹ Earnings per share are based on the average number of ordinary shares outstanding during the year. In calculating the earnings per share for the year, the dividend to which the preferential shares are entitled was taken into consideration, which reduced the year's earnings by SEK 28.0 million (reduction: 26.9). As per 31 December 2006, 8,047,306 (8,047,306) preferential shares were entitled to a cumulative dividend of SEK 81.9 million (53.9).

² Dilution effects occur only in those cases a conversion causes a decrease in earnings per share. For this reason, no dilution effect occurred during 2006.

³ Comparative figures regarding earnings per share have been restated on account of the transition to IFRS accounting.

Key figures

	31 Dec 2006	31 Dec 2005
Number of employees at end of period	47	39
Number of employees, average	43	39
Equity/assets ratio, %	78.8%	83.8%
Net cash/equity ratio, %	111.7%	93.6%
Shareholders' equity per share, SEK	136.78	199.97
Shareholders' equity per share after full dilution, SEK ⁴	10.39	15.67
Cash flow per share, SEK	-32.40	156.60
Cash flow per share after full dilution, SEK ⁴⁾	-3.22	16.50

⁴ Shareholders' equity per share after full dilution has been calculated under assumption that all potential ordinary shares have been converted into ordinary shares. No consideration has been taken in regards to change of shareholders' equity at conversion of warrants to ordinary shares.

Consolidated balance sheet

Amount in SEK millions	31 Dec 2006	31 Dec 2005
<i>Fixed assets</i>		
Tangible fixed assets	9.6	4.8
<i>Total fixed assets</i>	9.6	4.8
<i>Current assets</i>		
Accounts receivable	0.0	41.8
Other receivables	3.5	2.8
Deferred costs and accrued income	5.6	2.2
Liquid assets and short-term investments	154.8	187.2
<i>Total current assets</i>	164.0	234.0
Total assets	173.5	238.8
Shareholders' equity	136.8	200.0
Long-term liabilities	2.1	-
Long-term provisions	5.9	3.5
<i>Current liabilities</i>		
Accounts payable, trade	8.9	9.7
Other short-term liabilities	4.1	3.0
Accrued costs and deferred income	15.7	22.6
<i>Total current liabilities</i>	28.7	35.3
Total shareholders' equity and liabilities	173.5	238.8

Shareholders' equity

	Share Capital	Other paid-up capital	Retained earnings	Total equity
31 December 2004	0.9	374.5	-215.6	159.8
Effects of adoption of IFRS		0.0	-1.3	-1.3
01 January 2005	0.9	374.5	-216.8	158.6
Reduction of premium reserve		-215.6	215.6	
Net profit/loss for the year			34.7	34.7
Stock option plans		0.0		6.7
31 December 2005	0.9	158.9	40.2	200.0
Net profit/loss for the year			-70.5	-70.5
Stock option plans		0.0		7.3
31 December 2006	0.9	158.9	-23.0	136.8

Consolidated cash-flow statement

	Jan-Dec	Jan-Dec	Oct-Dec	Oct-Dec
Amount in SEK millions	2006	2005	2006	2005
Cash flow from operating activities ¹	-27.8	24.2	-22.0	89.5
Cash flow from investing activities	-8.2	-2.0	-1.3	-1.4
Cash flow from financing activities	3.6	134.4	-0.3	0.0
Cash flow for the period	-32.4	156.6	-23.6	88.1
Liquid funds, opening balance	187.2	30.6	178.4	99.1
Liquid funds, closing balance	154.8	187.2	154.8	187.2

¹ Of which, changes in working capital

	33.9	-19.3	-1.5	-22.2
--	------	-------	------	-------

Additional information to the cash-flow statement

	Jan-Dec	Jan-Dec	Oct-Dec	Oct-Dec
Amount in SEK millions	2006	2005	2006	2005
Interest paid and received				
Interest received and other financial income	1.0	0.8	0.2	0.2
Interest paid and other financial expense	-0.2	0.0	0.0	0.0
Depreciation and write-down of assets	3.4	2.0	0.9	0.5

Effects from implementing IFRS

The group's transition to accounting according to IFRS is reported according to IFRS 1 First-time Adoption of International Reporting Standards, which prescribes that also the comparative year shall be restated and presented according to IFRS. Financial information relating to fiscal years before 2005 is not reported.

On reviewing all accounting principles it was established that the standards IFRS 2 Share-based Payment and IAS 39 Financial Instruments: Recognition and Measurement involved changes for Biolipox. No further standards have been identified as applicable or involving any effect on the group's financial position and performance.

Adjustment of consolidated income statement related to adoption of IFRS

Amount in SEK millions	Note	Jan - Dec 2005			Oct - Dec 2005		
		Swedish GAAP	Effects of IFRS	IFRS	Swedish GAAP	Effects of IFRS	IFRS
Net revenue		147.0		147.0	147.0		147.0
Administrative costs	1	-22.2	-6.4	-28.6	-7.7	-2.0	-9.7
Research and development costs	2	-80.1	-2.6	-82.7	-22.5	-0.7	-23.2
Other operating revenues		1.8		1.8	0.9		0.9
Other operating costs		-2.0		-2.0	-1.8		-1.8
Operating profit/loss		44.4	-9.0	35.4	115.9	-2.7	113.2
<u>Result from net financial items</u>	3						
Interest income and similar items		2.1		2.1	0.3		0.3
Interest expense and similar items		0.0	-2.8	-2.8	0.0	-0.9	-0.9
Profit/loss after net financial items		46.5	-11.8	34.7	116.2	-3.6	112.6
Tax on earnings for the period		-		-	-		-
Net profit/loss for the period		46.5	-11.8	34.7	116.2	-3.6	112.6

	<u>Jan - Dec 2005</u>	<u>Oct - Dec 2005</u>
<u>Note 1 Administrative costs</u>		
Stock option plans, according to IFRS 2	-6.4	-2.0
<u>Note 2 Research and development costs</u>		
Stock option plans, according to IFRS 2	-2.6	-0.7
<u>Note 3 Result from net financial items</u>		
Unrealized exchange rate difference from forward exchange agreements according to IAS 39	-2.8	-0.9

Amount in SEK millions	Note	1 January 2005			31 December 2005		
		Swedish GAAP	Effects of IFRS	IFRS	Swedish GAAP	Effects of IFRS	IFRS
<i>Fixed assets</i>							
Tangible fixed assets		4.9		4.9	4.8		4.8
<i>Total fixed assets</i>		4.9		4.9	4.8		4.8
<i>Current assets</i>							
Accounts receivable		-		-	41.8		41.8
Other receivables		2.8		2.8	2.8		2.8
Deferred costs and accrued income		0.9		0.9	2.2		2.2
Receivables for subscribed but as yet unpaid share capital		135.4		135.4	-		-
Liquid assets and short-term investments		30.6		30.6	187.2		187.2
<i>Total current assets</i>		169.8		169.8	234.0		234.0
Total assets		174.7		174.7	238.8		238.8
Shareholders' equity	4	159.8	-1.3	158.5	206.3	-6.3	200.0
Long-term provisions	5	-	1.3	1.3	-	3.5	3.5
<i>Current liabilities</i>							
Accounts payable, trade		5.4		5.4	9.7		9.7
Other short-term liabilities		1.4		1.4	3.0		3.0
Accrued costs and deferred income	6	8.1		8.1	19.8	2.8	22.6
<i>Total current liabilities</i>		14.9		14.9	32.5		35.3
Total shareholders' equity and liabilities		174.7		174.7	238.8		238.8

	<u>1 January 2005</u>	<u>31 December 2005</u>
<u>Note 4 Shareholder's Equity</u>		
Stock option plans, according to IFRS 2	-1.3	-3.5
Unrealized exchange rate difference from forward exchange agreements according to IAS 39	-	-2.8
	<u>-1.3</u>	<u>-6.3</u>
<u>Note 5 Long-term provisions</u>		
Stock option plans, according to IFRS 2	1.3	3.5
	<u>1.3</u>	<u>3.5</u>
<u>Note 6 Accrued costs and deferred income</u>		
Unrealized exchange rate difference from forward exchange agreements according to IAS 39	-	2.8
	<u>-</u>	<u>2.8</u>

Adjustment of consolidated cash-flow statements relating to adoption of IFRS

Regarding the consolidated cash-flow statements, provisions for personnel costs relating to stock option plans and accrued exchange gains and losses on forward exchange agreements have affected changes in working capital. Cash-flow from operating activities before working capital changes have been affected by the corresponding amount. The transition to accounting according to IFRS has not implied any further changes in the consolidated cash-flow statements.

Stockholm, 21 February 2007

Biolipox AB (publ)
Torbjörn Bjerke, President & CEO

For further information, please contact:

Torbjörn Bjerke, President & CEO, Tel: +46-70-866 19 90,

e-mail: torbjorn.bjerke@biolipox.com.

Peter Hein, VP & CFO, Tel : +46-8-524 831 10, or +46-73-370 73 43

e-mail : peter.hein@biolipox.com

Biolipox AB (publ) (Corporate registration no. 556588-3658)

Berzeliusv 3, level 5

SE-171 65 Solna

Tel: +46-8-524 831 00

Fax +46-8-524 831 01

E-mail: info@biolipox.com

Internet: www.biolipox.com